HK1065478A1 - Treatment for attention-deficit hyperactivity disorder - Google Patents
Treatment for attention-deficit hyperactivity disorderInfo
- Publication number
- HK1065478A1 HK1065478A1 HK04108300.4A HK04108300A HK1065478A1 HK 1065478 A1 HK1065478 A1 HK 1065478A1 HK 04108300 A HK04108300 A HK 04108300A HK 1065478 A1 HK1065478 A1 HK 1065478A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hyperactivity disorder
- attention
- treatment
- deficit hyperactivity
- hyperactivity
- Prior art date
Links
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 title abstract 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 title abstract 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 title 1
- WVLHGCRWEHCIOT-UHFFFAOYSA-N eltoprazine Chemical compound C1CNCCN1C1=CC=CC2=C1OCCO2 WVLHGCRWEHCIOT-UHFFFAOYSA-N 0.000 abstract 1
- 229950006047 eltoprazine Drugs 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30682501P | 2001-07-20 | 2001-07-20 | |
US38293102P | 2002-05-23 | 2002-05-23 | |
PCT/US2002/023081 WO2003007956A1 (en) | 2001-07-20 | 2002-07-19 | Treatment for attention-deficit hyperactivity disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1065478A1 true HK1065478A1 (en) | 2005-02-25 |
Family
ID=26975388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04108300.4A HK1065478A1 (en) | 2001-07-20 | 2004-10-21 | Treatment for attention-deficit hyperactivity disorder |
Country Status (11)
Country | Link |
---|---|
US (5) | US7504395B2 (xx) |
EP (2) | EP2036547A3 (xx) |
JP (1) | JP5080716B2 (xx) |
AT (1) | ATE424825T1 (xx) |
AU (2) | AU2002322539B2 (xx) |
CA (1) | CA2453837C (xx) |
DE (1) | DE60231507D1 (xx) |
DK (1) | DK1408976T5 (xx) |
ES (1) | ES2323451T7 (xx) |
HK (1) | HK1065478A1 (xx) |
WO (1) | WO2003007956A1 (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
ATE424825T1 (de) * | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
US8751031B2 (en) * | 2004-02-06 | 2014-06-10 | Zircore, Llc | System and method for mass custom manufacturing of dental crowns and crown components |
JP2009500425A (ja) | 2005-07-06 | 2009-01-08 | セプラコア インコーポレーテッド | エスゾピクロン及びトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−n−メチル−1−ナフタレンアミン又はトランス4−(3,4−ジクロロフェニル)−1,2,3,4−テトラヒドロ−1−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法 |
US9066903B2 (en) | 2006-02-28 | 2015-06-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Pharmacological treatment of Parkinson's disease |
EP2374459A1 (en) * | 2008-05-30 | 2011-10-12 | Psychogenics Inc. | Treatment for neurological and mental disorders |
US20120077818A1 (en) * | 2009-05-13 | 2012-03-29 | Sunovion Pharmaceuticals Inc. | Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof |
EP2445498A1 (en) * | 2009-06-25 | 2012-05-02 | Alcobra Ltd. | A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition |
WO2011000562A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of certain movement disorders |
EP2448579A1 (en) | 2009-06-30 | 2012-05-09 | Merz Pharma GmbH & Co. KGaA | Eltoprazine for the treatment of weight disorders |
WO2011000565A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of anxiety |
WO2011000564A1 (en) | 2009-06-30 | 2011-01-06 | Merz Pharma Gmbh & Co. Kgaa | Eltoprazine for the treatment of drug addiction |
US8894415B2 (en) * | 2009-09-29 | 2014-11-25 | Advanced Training System Llc | System, method and apparatus for driver training |
WO2014180556A1 (en) * | 2013-05-06 | 2014-11-13 | Merz Pharma Gmbh & Co. Kgaa | Arylpiperazines |
JP7406285B1 (ja) | 2023-03-09 | 2023-12-27 | 国立大学法人島根大学 | ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンudp-グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物 |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4039653A (en) * | 1974-01-23 | 1977-08-02 | Defoney, Brenman, Mayes & Baron | Long-acting articles for oral delivery and process |
CH653021A5 (fr) | 1981-04-24 | 1985-12-13 | Delalande Sa | Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant. |
FR2524312B1 (fr) * | 1982-04-01 | 1985-10-04 | Tech Cuir Centre | Nouvelles formes de micro-encapsulation de substances medicamenteuses par des couches homogenes de collagene natif |
ZA848005B (en) | 1983-10-17 | 1985-05-29 | Duphar Int Res | Blood-pressure lowering piperazine derivatives |
EP0189612B1 (en) | 1984-12-21 | 1992-11-04 | Duphar International Research B.V | New pharmaceutical compositions having a psychotropic activity |
EP0190472B1 (en) | 1984-12-21 | 1989-07-12 | Duphar International Research B.V | New pharmaceutical compositions having anti-psychotic properties |
GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
US4797286A (en) * | 1985-11-12 | 1989-01-10 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
DK93087A (da) | 1986-02-27 | 1987-08-28 | Duphar Int Res | Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber |
GB8613689D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
DK172628B1 (da) | 1987-09-11 | 1999-08-02 | Duphar Int Res | Anvendelse af piperazinderivater til fremstilling af lægemidler til behandling af syndromer, der involverer frygt eller fry |
US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
IL92544A0 (en) | 1988-12-08 | 1990-08-31 | Duphar Int Res | Piperazine derivatives,their preparation and pharmaceutical compositions containing them |
GB8830312D0 (en) | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
SE8904361D0 (sv) | 1989-12-22 | 1989-12-22 | Astra Ab | New chroman and thiochroman derivatives |
FR2670491B1 (fr) | 1990-12-14 | 1993-02-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
MX9201991A (es) | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
IT1251144B (it) | 1991-07-30 | 1995-05-04 | Boehringer Ingelheim Italia | Derivati del benzimidazolone |
GB9125900D0 (en) | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
EP0556889A1 (en) | 1992-02-18 | 1993-08-25 | Duphar International Research B.V | Method of preparing aryl(homo)piperazines |
FR2692264B1 (fr) | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
DK148392D0 (da) | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
EP0939135A1 (en) | 1992-12-21 | 1999-09-01 | Duphar International Research B.V | Substantially pure hetero-bicyclic alcohol enantiomers |
RU2118322C1 (ru) | 1993-07-05 | 1998-08-27 | Дюфар Интернэшнл Рисерч Б.В. | 2,3-дигидро-1,4-бензодиокси-5-ил-пиперазиновые производные или их соли |
KR0177894B1 (ko) * | 1993-07-28 | 1999-03-20 | 아만 히데아키 | 항우울제 |
EP0724580A1 (en) | 1993-10-19 | 1996-08-07 | Smithkline Beecham Plc | Benzanilide derivatives as 5ht-1d receptor antagonists |
EP0650964A1 (en) | 1993-11-02 | 1995-05-03 | Duphar International Research B.V | 1 2H-1-benzopyran-2-one-8-yl -piperazine derivatives |
IL112764A0 (en) | 1994-03-18 | 1995-05-26 | Ferrer Int | New chromene derivatives |
CN1064350C (zh) | 1994-06-29 | 2001-04-11 | 辉瑞大药厂 | 芳基和杂芳基烷氧基萘衍生物 |
FR2725623A1 (fr) * | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
EP0710481A1 (en) | 1994-11-02 | 1996-05-08 | Duphar International Research B.V | Use of flesinoxan for cognition enhancement |
JPH10510253A (ja) | 1994-12-07 | 1998-10-06 | ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウラシル誘導体 |
US5741789A (en) * | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
WO1997003067A1 (en) | 1995-07-13 | 1997-01-30 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
GB9514901D0 (en) | 1995-07-20 | 1995-09-20 | American Home Prod | Piperazine derivatives |
SE9601110D0 (sv) * | 1996-03-22 | 1996-03-22 | Astra Ab | Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
ATE340173T1 (de) | 1996-03-29 | 2006-10-15 | Duphar Int Res | Piperazin- und piperidin- derivate |
US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
WO1998016530A1 (en) | 1996-10-15 | 1998-04-23 | American Home Products Corporation | AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONE |
FR2760014B1 (fr) | 1997-02-27 | 1999-04-09 | Adir | Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
DE19730989A1 (de) * | 1997-07-18 | 1999-01-21 | Merck Patent Gmbh | Piperazin-Derivate |
DE69819173T2 (de) | 1997-07-25 | 2004-04-15 | H. Lundbeck A/S | Indole und 2,3-dihydroindolderivate, ihre herstellung und verwendung |
US5942244A (en) * | 1997-07-31 | 1999-08-24 | Farmo-Nat Ltd. | Local oral herbal slow release tablets |
ATE253058T1 (de) | 1997-09-02 | 2003-11-15 | Duphar Int Res | Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten |
SE9703374D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
SE9703378D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | New compounds |
SE9703375D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
SE9703376D0 (sv) | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
FR2769312B1 (fr) | 1997-10-03 | 1999-12-03 | Adir | Nouveaux composes de l'indanol, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
IL127497A (en) | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
US6310066B1 (en) | 1998-04-29 | 2001-10-30 | American Home Products Corp. | Antipsychotic indolyl derivatives |
US6387904B2 (en) | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
DE69910706T2 (de) | 1998-05-26 | 2004-07-08 | Pfizer Products Inc., Groton | Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie |
GB9812523D0 (en) * | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6376494B1 (en) | 1998-06-15 | 2002-04-23 | American Home Products Corporation | Cycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents |
US6242448B1 (en) | 1998-12-17 | 2001-06-05 | American Home Products Corporation | Trisubstituted-oxazole derivatives as serotonin ligands |
US6313126B1 (en) | 1999-01-07 | 2001-11-06 | American Home Products Corp | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
US6306859B1 (en) | 1999-03-02 | 2001-10-23 | American Home Products Corporation | N-substituted imide derivatives with serotonergic activity |
ES2162731B1 (es) | 1999-06-04 | 2003-02-16 | Faes Fabrica Espanola De Produ | Nuevas arilpiperacilnilalquil-3(2h)-piridacinonas. |
CA2380531A1 (en) | 1999-07-29 | 2001-02-08 | Mark Louis Heiman | Benzofurylpiperazine serotonin agonists |
JP2003506365A (ja) * | 1999-07-29 | 2003-02-18 | イーライ・リリー・アンド・カンパニー | ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト |
AR027133A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de heteroarilo, su preparacion y uso. |
DZ3370A1 (fr) | 2000-05-12 | 2001-11-15 | Solvay Pharm Bv | Composes de piperazine et piperidine |
AU2001267421A1 (en) | 2000-05-12 | 2001-11-20 | Solvay Pharmaceuticals B.V. | Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
US20020016334A1 (en) | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
DE10043659A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
NZ525592A (en) * | 2000-11-02 | 2004-07-30 | Wyeth Corp | 1-Aryl- or 1-alkylsufonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
US6469007B2 (en) | 2000-11-28 | 2002-10-22 | Wyeth | Serotonergic agents |
ES2188344B1 (es) | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
AR032711A1 (es) | 2001-02-21 | 2003-11-19 | Solvay Pharm Bv | Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene |
SI1399438T1 (sl) | 2001-06-29 | 2006-04-30 | Lundbeck & Co As H | Novi heteroarilni derivati, njihova priprava in uporaba |
ATE424825T1 (de) | 2001-07-20 | 2009-03-15 | Psychogenics Inc | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten |
HU227237B1 (en) | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
ITMI20012060A1 (it) | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
EP1336406A1 (en) | 2002-02-14 | 2003-08-20 | Solvay Pharmaceuticals B.V. | Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity |
RU2315044C2 (ru) | 2002-03-12 | 2008-01-20 | Уайт | Способ получения хиральных 1,4-дизамещенных пиперазинов |
KR20040091720A (ko) | 2002-03-12 | 2004-10-28 | 와이어쓰 | N1-(2'-피리딜)-1,2-프로판디아민 설팜산의 제조방법 및생물학적 활성 피페라진 합성시의 이의 용도 |
MXPA04008729A (es) | 2002-03-12 | 2005-07-13 | Wyeth Corp | Proceso para sintetizacion de piperazinas n-arilicas quirales. |
WO2003095434A1 (en) | 2002-05-13 | 2003-11-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
US20040072839A1 (en) | 2002-06-14 | 2004-04-15 | Amedeo Leonardi | 1-Phenylalkylpiperazines |
US20040002500A1 (en) | 2002-06-28 | 2004-01-01 | Fabre Kramer Pharmaceutical, Inc. | Methods for treating attention deficit disorder |
US7067518B2 (en) | 2002-09-05 | 2006-06-27 | Wyeth | Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents |
US7153849B2 (en) | 2002-09-12 | 2006-12-26 | Wyeth | Antidepressant arylpiperazine derivatives of hetrocycle-fused benzodioxans |
PL377770A1 (pl) | 2002-11-08 | 2006-02-20 | F. Hoffmann-La Roche Ag | Podstawione benzoksazynony i ich zastosowanie |
US20040147581A1 (en) | 2002-11-18 | 2004-07-29 | Pharmacia Corporation | Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy |
WO2004069339A1 (en) | 2003-01-29 | 2004-08-19 | Psychogenics Inc. | Treatment for attention-deficit hyperactivity disorder |
WO2004078176A1 (en) | 2003-03-03 | 2004-09-16 | F. Hoffmann-La Roche Ag | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
JP2007522095A (ja) | 2003-05-16 | 2007-08-09 | ファイザー・プロダクツ・インク | ジプラシドンを用いた不安の治療 |
BRPI0410378A (pt) | 2003-05-16 | 2006-06-13 | Pfizer Prod Inc | tratamento de distúrbios psicóticos e depressivos |
EP1626723A1 (en) | 2003-05-16 | 2006-02-22 | Pfizer Products Inc. | Treatment of bipolar disorders and associated symptoms |
CA2525323A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
US20050065158A1 (en) | 2003-07-16 | 2005-03-24 | Pfizer Inc. | Treatment of sexual dysfunction |
US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
CN100532369C (zh) | 2003-12-09 | 2009-08-26 | 弗·哈夫曼-拉罗切有限公司 | 苯并噁嗪衍生物及其用途 |
-
2002
- 2002-07-19 AT AT02756536T patent/ATE424825T1/de not_active IP Right Cessation
- 2002-07-19 JP JP2003513563A patent/JP5080716B2/ja not_active Expired - Fee Related
- 2002-07-19 DE DE60231507T patent/DE60231507D1/de not_active Expired - Lifetime
- 2002-07-19 AU AU2002322539A patent/AU2002322539B2/en not_active Ceased
- 2002-07-19 US US10/199,634 patent/US7504395B2/en not_active Expired - Fee Related
- 2002-07-19 EP EP08173141A patent/EP2036547A3/en not_active Withdrawn
- 2002-07-19 DK DK02756536.5T patent/DK1408976T5/da active
- 2002-07-19 CA CA2453837A patent/CA2453837C/en not_active Expired - Fee Related
- 2002-07-19 ES ES02756536T patent/ES2323451T7/es active Active
- 2002-07-19 EP EP02756536A patent/EP1408976B3/en not_active Expired - Lifetime
- 2002-07-19 WO PCT/US2002/023081 patent/WO2003007956A1/en active Application Filing
-
2004
- 2004-10-21 HK HK04108300.4A patent/HK1065478A1/xx not_active IP Right Cessation
-
2005
- 2005-09-02 US US11/219,416 patent/US7557109B2/en not_active Expired - Fee Related
-
2007
- 2007-12-24 AU AU2007254677A patent/AU2007254677B2/en not_active Ceased
-
2008
- 2008-12-24 US US12/344,051 patent/US20090104261A1/en not_active Abandoned
-
2010
- 2010-09-20 US US12/885,822 patent/US20110008425A1/en not_active Abandoned
-
2011
- 2011-08-16 US US13/210,474 patent/US20120070494A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2036547A3 (en) | 2009-12-23 |
DK1408976T5 (da) | 2011-01-10 |
US20090104261A1 (en) | 2009-04-23 |
ES2323451T7 (es) | 2011-08-01 |
CA2453837C (en) | 2011-10-04 |
EP2036547A2 (en) | 2009-03-18 |
JP2004538282A (ja) | 2004-12-24 |
US7504395B2 (en) | 2009-03-17 |
AU2002322539B2 (en) | 2007-09-27 |
DE60231507D1 (de) | 2010-07-01 |
US20120070494A1 (en) | 2012-03-22 |
ES2323451T3 (es) | 2009-07-16 |
US20110008425A1 (en) | 2011-01-13 |
JP5080716B2 (ja) | 2012-11-21 |
US20060004023A1 (en) | 2006-01-05 |
ATE424825T1 (de) | 2009-03-15 |
EP1408976B1 (en) | 2009-03-11 |
US7557109B2 (en) | 2009-07-07 |
CA2453837A1 (en) | 2003-01-30 |
EP1408976A4 (en) | 2007-05-16 |
US20030050308A1 (en) | 2003-03-13 |
EP1408976B3 (en) | 2010-08-25 |
DK1408976T3 (da) | 2009-06-29 |
AU2007254677A1 (en) | 2008-01-24 |
WO2003007956A1 (en) | 2003-01-30 |
AU2007254677B2 (en) | 2009-11-12 |
EP1408976A1 (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1065478A1 (en) | Treatment for attention-deficit hyperactivity disorder | |
HK1159514A1 (en) | Ht0712 for the treatment of a cognitive deficit ht0712 | |
ATE415968T1 (de) | 3,11b-cis-dihydrotetrabanezin zur behandlung von schizophrenie und anderen psychosen | |
HK1073608A1 (en) | Treatment of alpha-galactosidase a deficiency | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
PL362690A1 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
ATE296634T1 (de) | (s,s)-reboxetin zur behandlung von fibromyalgie und anderen somatoformen störungen | |
HK1103354A1 (en) | Combination therapy for preventing or treating alzheimers disease, and kit therefor | |
BRPI0418589A (pt) | composições farmacêuticas e métodos para tratamento por insulina | |
EP1533395A4 (en) | METHOD FOR MANUFACTURING A STAINLESS STEEL PRODUCT BY NITROGEN ABSORPTION TREATMENT AND STAINLESS STEEL PRODUCT OBTAINED ACCORDING TO SAID PROCESS | |
HRP20050075A2 (en) | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | |
NL1021504A1 (nl) | Waterstofbehandelingsproces. | |
HK1080408A1 (en) | Use of brimonidine in the treatment of dementia a nd parkinson | |
EP2292666A3 (en) | Neoplasm specific antibodies and uses thereof | |
HUP0303303A3 (en) | Treatment bed, treatment apparatus and treatment device | |
DE50300918D1 (de) | Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien | |
ZA200101058B (en) | Process for the treatment of gases. | |
EP1406605A4 (en) | 2-HETEROCYCLIC 1,2-ETHANEDIOL CARBAMATES | |
AU2003265321A8 (en) | Treatments and methods for the treatment, diagnosis and prophylaxis | |
RU2002114913A (ru) | Способ лечения вторичной гипоэстрогении | |
DE9314724U1 (de) | Antriebs- und Beleuchtungseinrichtung für Krankenbetten, Behandlungsstühle u.dgl. | |
ATE300961T1 (de) | Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfaehiger medien | |
RU2001112731A (ru) | Способ лечения онкологических больных | |
TW200635580A (en) | Methods of treatment and prevention | |
UA67138A (en) | Method for treating chlamidia-associated reactive arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190719 |